Profound inhibition of antigen-specific T-cell effector functions by dasatinib

Ralf Weichsel, Carolin Dix, Linda Wooldridge, Matthew Clement, Angharad Fenton-May, Andrew K Sewell, Josef Zezula, Elisabeth Greiner, Emma Gostick, David A Price, Hermann Einsele, Ruth Seggewiss

Research output: Contribution to journalArticle (Academic Journal)peer-review

119 Citations (Scopus)


The dual BCR-ABL/SRC kinase inhibitor dasatinib entered the clinic for the treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. Because SRC kinases are known to play an important role in physiologic T-cell activation, we analyzed the immunobiological effects of dasatinib on T-cell function. The effect of dasatinib on multiple T-cell effector functions was examined at clinically relevant doses (1-100 nmol/L); the promiscuous tyrosine kinase inhibitor staurosporine was used as a comparator.
Original languageEnglish
Pages (from-to)2484-91
Number of pages8
JournalClinical Cancer Research
Issue number8
Publication statusPublished - 15 Apr 2008


  • Apoptosis
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Humans
  • Immunologic Memory
  • Interleukin-2
  • Lymphocyte Activation
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptor-CD3 Complex, Antigen, T-Cell
  • Receptors, Antigen, T-Cell
  • Staurosporine
  • T-Lymphocytes
  • Thiazoles


Dive into the research topics of 'Profound inhibition of antigen-specific T-cell effector functions by dasatinib'. Together they form a unique fingerprint.

Cite this